Lung cancer study finds new target for treatment resistance after EGFR inhibitors
Preclinical study demonstrates targeting CD70 with cell therapies, antibody-drug conjugates can eliminate resistant tumor cells
MD Anderson News Release February 13, 2023
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors (TKIs). The study published today in Cancer Cell.
The preclinical research was led by Monique Nilsson, Ph.D., and corresponding author John Heymach, M.D., Ph.D., chair of Thoracic/Head and Neck Medical Oncology. The researchers discovered that CD70, a cell surface protein normally found on immune cells, is highly overexpressed in resistant cells as well as in the residual cancer cells immediately following TKI treatment. They demonstrated that CD70 can be effectively used to target these cells with antibody-drug conjugates (ADCs) or cell therapies in laboratory models.
“Residual cancer cells left over from TKI treatment are essentially a reservoir from which future resistant cells eventually grow,” Heymach said. “These findings set the stage for a really promising approach in which we may give initial effective therapies and immediately follow them with these CD70-targeting drugs to eliminate the remaining residual cells.”
Approximately 10-15% of patients with NSCLC have EGFR mutations. While treatment with EGFR TKIs is effective at killing most cancer cells, a small number of drug-tolerant cells persist. These cells can remain dormant, even invisible, for long periods of time, but they eventually grow and metastasize.
Tumor cells can become resistant to EGFR TKIs through several mechanisms, including epithelial-to-mesenchymal transition (EMT). Tumors that have undergone EMT become broadly resistant to most known drugs, leading to a poor prognosis for relapsed patients and underscoring a critical unmet need to understand the mechanisms behind this acquired resistance.
The researchers in the study identified CD70 by conducting an integrated analysis of cell surface proteins in treatment-resistant NSCLC cells. Further investigation revealed that CD70 overexpression was also upregulated on the residual drug-tolerant cells, suggesting that increased CD70 is an early event in the development of resistant disease.
“It was really encouraging to discover that CD70 was upregulated at such an early point in the evolution of drug resistance because it means we can target these cells quickly without needing to wait for them to develop full resistance,” Nilsson said.
Building on this discovery, the researchers demonstrated that CD70 could be used effectively to target these cells both in vitro and in vivo. Anti-CD70 ADCs as well as CD70-targeting chimeric antigen receptor (CAR) T cells and CAR natural killer (NK) cells each had significant anti-tumor activity, eliminating drug-tolerant residual cells in laboratory models.
While this study looked at CD70 in the context of lung cancer, its overexpression also is found in a number of different cancer types such as breast, pancreatic, ovarian, kidney and melanoma.
“We believe that the lessons we’ve learned from EGFR inhibitor resistance may be more broadly applicable, extending beyond these mutations and possibly applying to other tumor types that eventually develop EMT or other types of treatment resistance mechanisms,” Heymach said.
The authors point out that CD70-based therapeutic strategies currently are in clinical trials for other malignancies, and that the next steps would be to apply them to this specific disease setting.
This study was supported by the Mugnaini Fund, the David Bruton, Jr. Chair, Rexanna’s Foundation for Fighting Lung Cancer, the National Institutes of Health/National Cancer Institute (5 P40 CA070907, CA016672, 1R01CA247975, 1R01CA190628, 1R50CA265307, 1R01CA240257, and 1R01CA234183-01A1), MD Anderson’s Lung Cancer Moon Shot®, the Lerryn M. Carl Endowment for Lung Cancer Research, Stading Fund for EGFR inhibitor resistance, the Fox Lung EGFR Inhibitor Fund, the Hanlon Fund, the Richardson Fund, The Kopelman Foundation, the Hallman Fund, the Exon 20 Group, and the Cancer Prevention and Research Institute of Texas (CPRIT) (RP120348 and RP170002). A full list of co-authors and author disclosures can be found here.